TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21442171
Drug: 12-week supervised
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week supervised training programme consisting of 3 weekly sessions of aerobic, strengthening and flexibility exercises
Study: 15845756
Drug: Lamotrigine (LTG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (LTG, 100 mg-400 mg/day, mean modal dose 240 mg)
Study: 15845756
Drug: Lithium (Li,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (Li, 0.8 mEq/L-1.1 mEq/L, mean modal dose 750 mg)
Study: 7622805
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) reuptake inhibitors
Study: 7622805
Drug: Mixed NE/serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed NE/serotonin reuptake inhibitors
Study: 17557453
Drug: eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eszopiclone 3 mg (cotherapy)
Study: 17557453
Drug: placebo (monotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (monotherapy)
Study: 15805382
Drug: Standard 2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2-dose regimen of TIV administered in the fall
Study: 15805382
Drug: Early schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early schedule of a single spring dose followed by a fall dose of TIV
Study: 15805382
Drug: TIV with
Normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV with concomitant vaccines
Study: 12087544
Drug: Bleaching treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching treatments (various concentrations) for 7 or 14 days
Study: 12087544
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (water instead of bleaching gel)
Study: 2694604
Drug: 250, 500,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250, 500, or 1,000 mg/kg of IVIG plus antibiotics
Study: 820104
Drug: Nitroglycerin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (5 mg)
Study: 28030534
Drug: Patients off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients off steroids
Study: 21563503
Drug: Jingyuankang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingyuankang capsule
Study: 21563503
Drug: Leucogen tablet
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Leucogen tablet
Study: 19290019
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment
Study: 11242482
Drug: Modified sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified sham feeding a low-fat meal (6 g fat)
Study: 11242482
Drug: Modified sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified sham feeding a moderate-fat meal (38 g fat)
Study: 23387822
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activator [t‐PA], mechanical clot disruption or retrieval, or a combination of these approaches)
Study: 18761238
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 microg/kg bolus, 0.05 microg/kg per min infusion)
Study: 18761238
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 microg/kg bolus, 0.5 microg/kg bolus doses)
Study: 16471102
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg IV administered twice
Study: 16471102
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg IV administered twice
Study: 12939421
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day (after 5 mg/day for the first 28 days)
Study: 10481525
Drug: Immunofluorescence with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunofluorescence with MAC‐1, MAC‐31, NSE and anti‐Fucosyl‐GM1 (PF3) antibodies
Study: 8784635
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in the NG group
Study: 8784635
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in the G group
Study: 1810999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dibenzoylmethane derivative and physical agents
Study: 1810999
Drug: Physical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical agents
Study: 6925982
Drug: Single intrapleural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intrapleural injection of BCG
Study: 29777003
Drug: Aducanumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (1 mg/kg)
Study: 29777003
Drug: Aducanumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (3 mg/kg)
Study: 29777003
Drug: Aducanumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (6 mg/kg)
Study: 29777003
Drug: Aducanumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (10 mg/kg)
Study: 22476230
Drug: Candesartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan treatment (+ thiazide diuretics)
Study: 18410608
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks
Study: 18410608
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy continuously
Study: 18410608
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Talpha1 and lamivudine
Study: 12016348
Drug: Magnetic field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic field treatment
Study: 12016348
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication (diclofenac and tizanidine)
Study: 8830065
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg per day for 8 weeks)
Study: 35196
Drug: Clobazam (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (10-60 mg daily)
Study: 35196
Drug: Clobazam (49
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (49 mg daily)
Study: 31216852
Drug: Palliative systemic
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative systemic therapy
Study: 23242758
Drug: Bacterial lysate
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial lysate (Escherichia coli and Enterococcus faecalis), prophylactic treatment for 26 weeks
Study: 15314546
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (3 x 10(6) IU/m2/day) administered daily for 6 weeks with a weekly melanoma peptide vaccine.
Study: 11332212
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 1 mg gemeprost (group 2A, n: 17)
Study: 9329410
Drug: Heparin (1
Normalized name: 2,3-o-Desulfated heparin (12000 da)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1 unit per milliliter in umbilical catheter infusate)
Study: 1640278
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (control group)
Study: 26174571
Drug: Non-splint multimodal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-splint multimodal therapy plus stabilisation splint (NS+S)
Study: 26174571
Drug: Non-splint multimodal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-splint multimodal therapy (NS)
Study: 19597412
Drug: Polyglucosamine (PG)
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyglucosamine (PG) 2 g/day
Study: 14572565
Drug: 6.5-h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5-h infusion of gabexate (500 mg total)
Study: 14572565
Drug: 13-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-h infusion of gabexate (1 g total)
Study: 10629468
Drug: 2-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-component acellular pertussis vaccine (APV) composed of pertussis toxin and filamentous hemagglutinin
Study: 10629468
Drug: Meningococcal vaccine
Normalized name: Meningococcal vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal vaccine (control)
Study: 8959467
Drug: Ethanol (0.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.55 g/kg of body weight)
Study: 1326741
Drug: D x
Normalized name: Bind X Brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: D x RRV vaccine (10^4 plaque-forming units/1-ml dose)
Study: 1326741
Drug: DS 1
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS 1 x RRV vaccine (10^5 plaque-forming units/1-ml dose)
Study: 4048752
Drug: Cefoperazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (2 g/d)
Study: 4048752
Drug: Ampicillin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (6 g/d) + Tobramycin (3 to 4 mg/kg/d)
Study: 29553834
Drug: 2% dill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dill vaginal suppositories
Study: 29553834
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clotrimazole vaginal tablets
Study: 20151971
Drug: UK-369,003 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-369,003 (10, 25, 50 or 100 mg once a day for 12 weeks)
Study: 16437657
Drug: 5‐ASA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA (50 mg/kg/d) + omega‐3 FAs (3 g/d, EPA 400 mg/g, DHA 200 mg/g)
Study: 16437657
Drug: 5‐ASA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA (50 mg/kg/d) + olive oil placebo capsules
Study: 1421640
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium 1000 units/mL
Study: 6399890
Drug: Oral frusemide/amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral frusemide/amiloride combination tablet (40 mg frusemide and 5 mg amiloride)
Study: 6399890
Drug: Commercially-available 40
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially-available 40 mg frusemide tablets
Study: 6399890
Drug: Commercially-available 5
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially-available 5 mg amiloride tablets
Study: 31033190
Drug: Metoprolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol treatment in PEAR-2 study
Study: 31033190
Drug: Atenolol treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol treatment in PEAR study
Study: 22892323
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day + statin
Study: 22892323
Drug: double-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-dose statin
Study: 11281486
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g intravenously after induction of anesthesia (PA group)
Study: 8338261
Drug: 35 ml
Normalized name: ethanol 0.35 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ml of 1.5% lidocaine with 1 in 200,000 of adrenaline (Group A)
Study: 8338261
Drug: 1 microgram.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram.kg‐1 of fentanyl with the same dose of lidocaine (Group B)
Study: 3525976
Drug: Antazoline (Antistine)
DrugBank: Antazoline (DB08799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antazoline (Antistine) in addition to conventional immunosuppressive therapy (group A)
Study: 3525976
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive therapy only (group B)
Study: 31665935
Drug: Dexamethasone 0.7
Normalized name: dexamethasone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.7 mg implant
Study: 22519919
Drug: Imeglimin 2000
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 2000 mg once daily
Study: 22519919
Drug: Imeglimin 500
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 500 mg twice daily
Study: 22519919
Drug: Imeglimin 1500
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 1500 mg twice daily
Study: 10619726
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific therapy for funguria
Study: 10619726
Drug: Catheter removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter removal as the only treatment
Study: 1300186
Drug: Early surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surgical treatment of contractures (release of hip flexors, removal of iliotibial bands, lengthening of tendo Achilles bilaterally)
Study: 29096686
Drug: No supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplementation for patients with normal vitamin D levels (≥50 nmol/L)
Study: 18825439
Drug: Donepezil or
Normalized name: donepezil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil or Vitamin E (exact dosage and duration not specified)
Study: 12477583
Drug: Remifentanil (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (n = 1,229) 0.5 microg/kg/min for induction and tracheal intubation followed by an infusion rate of 0.25 microg/kg/min
Study: 12477583
Drug: Fentanyl (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (n = 1,209) administered according to the anesthesiologist's usual practice
Study: 1935150
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg iv or 800 mg iv over 20 mins, followed by three 800-mg doses rectally every 6 hrs)
Study: 30948695
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) administered in the preoperative and intraoperative periods
Study: 26148587
Drug: Oxitard capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitard capsules (2 capsules twice daily for 3 months)
Study: 26148587
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 3 months)
Study: 21295833
Drug: eLH (equine
Approvals — FDA: no, EMA: no, PMDA: no
Description: eLH (equine LH) administered intravenously every 12 h from the day the largest follicle reached 20 mm until a follicle reached >32 mm
Study: 21295833
Drug: Saline (transitional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (transitional control) administered in the same manner as eLH
Study: 21295833
Drug: hCG (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG (3000 IU) administered after a follicle reached >32 mm
Study: 17665051
Drug: Valdecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (40 mg)
Study: 26463567
Drug: Aspiration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration with steroid injection (AS)
Study: 23992241
Drug: Multidisciplinary depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary depression management program (including activating strategies, psychotherapy, and medication)
Study: 23992241
Drug: Pharmacological depression
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological depression treatment
Study: 20577017
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (prednisolone and cyclophosphamide)
Study: 10491487
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy with pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for 7 or 14 days
Study: 9005796
Drug: Ofloxacin administered
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin administered intravenously during the first days of treatment, followed by oral use
Study: 1820900
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg) alone
Study: 1820900
Drug: Lansoprazole with
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole with antacids (aluminium and magnesium hydroxides)
Study: 1820900
Drug: Lansoprazole administered
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole administered one hour after antacids
Study: 7091770
Drug: Pentaerythritol Tetranitrate
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythritol Tetranitrate (Peritrate) 40 mg chew-and-swallow tablets
Study: 30082141
Drug: Citalopram 4
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 4 mg (low group)
Study: 30082141
Drug: Citalopram 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 16 mg (high group)
Study: 26787345
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion analgesia (ED) with 0.2% Ropivacaine
Study: 23095007
Drug: estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol valerate in combination with testosterone undecanoate
Study: 17440526
Drug: Glutamine-supplemented HPN
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented HPN (10 g of glutamine)
Study: 25285531
Drug: Obatoclax 20
Normalized name: Obatoclax
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax 20 mg/day (3 h × 3 d)
Study: 25285531
Drug: Obatoclax 60
Normalized name: Obatoclax
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax 60 mg/day (24 h × 3 d)
Study: 22556172
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of omeprazole (OPZ), 40 mg single dose
Study: 22556172
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of omeprazole (OPZ)
Study: 15991879
Drug: Neodolpasse (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodolpasse (fixed-dose combination of orphenadrine and diclofenac)
Study: 9016417
Drug: Warfarin prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescribed
Study: 9016417
Drug: Warfarin judged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin judged appropriate
Study: 9016417
Drug: Warfarin prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescribed to older patients
Study: 1352024
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg + dexamethasone 20 mg
Study: 1352024
Drug: Metoclopramide 3
Normalized name: metoclopramide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 3 mg/kg + dexamethasone + diphenhydramine 50 mg
Study: 3848264
Drug: Kallikrein 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein 600 units daily for 3-6 months
Study: 31051049
Drug: Medium lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium lithium concentration mineral water (171 µg L‐1)
Study: 31051049
Drug: High lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lithium concentration mineral water (1724 µg L‐1)
Study: 31051049
Drug: Low lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lithium concentration mineral water (1.7 µg L‐1)
Study: 9630129
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine
Study: 3075649
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (chiropractic adjustments of the thoracic spine T1-T5)
Study: 30509293
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump with flash glucose measurement (FGM) device
Study: 22526685
Drug: Minocycline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline plus treatment as usual (TAU)
Study: 22526685
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus treatment as usual (TAU)
Study: 9842818
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg (B)
Study: 9842818
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 microg + Bupivacaine 2.5 mg (F + B)
Study: 8077066
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral nicorandil (5, 10, 20, or 30 mg)
Study: 2684380
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 mg) administered BID, titrated to optimal dose
Study: 2684380
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg) administered BID, titrated to optimal dose
Study: 1189985
Drug: Glycerol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol infusion
Study: 1189985
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no glycerol infusion)
Study: 25449994
Drug: Dolutegravir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir administered 2 hours before calcium carbonate or ferrous fumarate, fasting
Study: 23377194
Drug: drospirenone-ethinyl estradiol
Normalized name: drospirenone-ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: drospirenone-ethinyl estradiol + metformin (M)